Zentalis Pharmaceuticals (ZNTL) Investor Presentation - Slideshow

ZN-c3 (Wee1 Inhibitor) - ZN-c3 has shown partial responses in four tumor types and has potential accelerated approval paths for USC and biomarker-driven trials[8] - Zentalis' ZN-c3-002 trial showed an overall objective response rate (ORR) of 302% in evaluable ovarian cancer patients, with a disease control rate (DCR) of 860%[51] - In a ZN-c3-001 study of USC patients, the overall response rate was 273% (95% CI = 60%, 610%) and the disease control rate (DCR) was 909% (95% CI = 587%, 998%)[67] - Preclinical data indicates that ZN-c3, when combined with Sotorasib, induces regressions in a KRAS/TP53 mutant colorectal cancer model[115] - In preclinical models, ZN-c3 combined with Niraparib shows regressions and is well-tolerated in a TNBC PDX tumor model[118] ZN-d5 (BCL-2 Inhibitor) - ZN-d5 has >14x improved selectivity for BCL-2 vs BCL-xL and binds with higher affinity to BCL-2 mutants than Venetoclax[132] - In AL Amyloidosis, 63% of patients achieved VGPR/CR (very good partial response/complete response)[150] - Early data in NHL shows a favorable toxicity profile for ZN-d5 compared to published venetoclax data[144] ZN-c3 & ZN-d5 Combination - Preclinical data suggests that the combination of ZN-d5 and ZN-c3 has synergistic and additive activity across multiple indications in both solid and liquid tumors[141] - In preclinical AML models, the combination of ZN-d5 and ZN-c3 resulted in a 94% regression[172] - In preclinical models, the combination of ZN-c3 with Navitoclax resulted in a 96% tumor growth inhibition (TGI)[192]